2. Signaling Pathways
  3. Anti-infection
  4. SARS-CoV

SARS-CoV

SARS coronavirus

SARS-CoV

Related Products

PDF 0.94 MB

SARS-CoV is the coronavirus (CoV) that causes severe acute respiratory syndrome (SARS). CoVs are enveloped viruses with a positive-sense, single-stranded RNA and can cause health-threatening outbreaks by targeting human respiratory system, including not only SARS, but also Middle East respiratory syndrome (MERS) and SARS-CoV-2 (the cause of COVID-19).

CoVs have four main structural proteins: spike(S), membrane (M), envelope (E), and nucleocapsid (N) proteins. An S protein mediates the CoV entry into host cells by attaching to a cellular receptor (ACE2 for SARS-CoV and SARS-CoV-2, DPP4 for MERS-CoV), followed by fusion between virus and host cell membranes. Genome replication and subgenomic RNA transcription after entry carry on with the participation of many nonstructural proteins such as Mpro (main protease or 3CLpro), PLpro (papain-like protease) and RdRp (RNA-dependent RNA polymerase). Then the structural proteins are translated, assembled into mature virions, and released via vesicles by exocytosis. It is worth mentioning that a protease called TMPRSS2 (transmembrane protease, serine 2) play important roles throughout the whole life of CoVs (such as attachment, assembling and release) by cleaving S protein. All the proteins and subcellular structures participated in the life cycle of CoVs are promising targets for treatment of disease caused by CoVs.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-155527
    SARS-CoV-2 Mpro-IN-9
    		Inhibitor 99.31%
    SARS-CoV-2 Mpro-IN-9 (compound c7) is a nonpeptidic, noncovalent SARS-CoV-2 Mpro inhibitor (IC50=0.085 μM), with improved physicochemical and drug metabolism and pharmacokinetics (DMPK) properties. SARS-CoV-2 Mpro-IN-9 inhibits viral replication (EC50=1.10 μM) in SARS-CoV-2-infected Vero E6 cells, while exhibits low cytotoxic effects (CC50>50 μM).
    SARS-CoV-2 Mpro-IN-9
  • HY-151271A
    SARS-CoV-2-IN-27 disodium
    		Inhibitor
    SARS-CoV-2-IN-27 disodium is a two-armed diphosphate ester with C6 alkyl and molecular tweezers with extended length. SARS-CoV-2-IN-27 disodium exhibits antiviral activity with IC50s of 1.0 μM and 1.7 μM against SARS-CoV-2 activity and the spike pseudoparticle transduction, respectively. SARS-CoV-2-IN-27 disodium induces liposomal membrane disruption with an EC50 value of 6.5 μM.
    SARS-CoV-2-IN-27 disodium
  • HY-127083
    Artecanin
    		Inhibitor
    Artecanin is a SARS-CoV-2 main protease (Mpro) inhibitor with predicted high gastrointestinal absorption and oral bioavailability, and no predicted hepatotoxicity, carcinogenicity, mutagenicity or cytotoxicity. Artecanin interacts with His41 and Cys145, the key amino acid residues in the active site of Mpro, blocks the cleavage and maturation of viral precursor proteins, and forms a stable complex with Mpro. Artecanin blocks the invasion of SARS-CoV-2. Artecanin is applicable to the research of COVID-19.
    Artecanin
  • HY-172965
    SARS-CoV-2 Mpro-IN-43
    SARS-CoV-2 Mpro-IN-43 (Compound 1) is a coronavirus main protease (Mpro) inhibitor (IC50: 72 μM). SARS-CoV-2 Mpro-IN-43 interacts with key residues in the active site of Mpro via non-covalent binding, exerting its anti-coronavirus effect. SARS-CoV-2 Mpro-IN-43 exhibits moderate to low cytotoxicity, with CC50 values of 13.24, 41.02, and 42.26 µM in HaCaT, HEK293T, and HepG2 cells, respectively. SARS-CoV-2 Mpro-IN-43 can be used in anti-SARS-CoV-2 research.
    SARS-CoV-2 Mpro-IN-43
  • HY-150783
    SARS-CoV-2-IN-24
    		Inhibitor
    SARS-CoV-2-IN-24 (compound 7) is a potent papain-like protease (PLpro) inhibitor. SARS-CoV-2-IN-24 induces conformational changes in SARS-COV-2 papain-like protease, inhibiting SARS-CoV-2 replication. SARS-CoV-2-IN-24 can be used for SARS-CoV-2 research.
    SARS-CoV-2-IN-24
  • HY-153719
    NSC111552
    		Inhibitor
    NSC111552 is a potent SARS-CoV-2 NSP14 MTase inhibitor. NSC111552 inhibits the FL-NAH binding to the SARS-CoV-2 NSP14 MTase with an IC50 of 5.1 μM.
    NSC111552
  • HY-151501
    Antimicrobial agent-11
    		Inhibitor
    Antimicrobial agent-11 is a SARS-CoV-2 inhibitor with antibacterial activity.
    Antimicrobial agent-11
  • HY-150691
    SARS 3CLpro-IN-1
    		Inhibitor
    SARS 3CLpro-IN-1 (Compound 3b) is a SARS 3CL protease inhibitor with an IC50 value of 95 μM, as a specific stereo isomer of the octahydroisochromene scaffold, directs the P1 site imidazole.
    SARS 3CLpro-IN-1
  • HY-162414
    SARS-CoV-2-IN-84
    		Inhibitor
    SARS-CoV-2-IN-84 (compound 20) is aSARS-CoV-2 inhibitor that targets the 3CL protease (3CL Pro) of SARS-CoV-2 (IC50: 369.5 nM ).
    SARS-CoV-2-IN-84
  • HY-P4307
    Antioxidant agent-9
    		Inhibitor
    Antioxidant agent-9 is a peptide with the sequence Asp-Trp. Antioxidant agent-9 shows antioxidant activity. Antioxidant agent-9 also is potential as SARS-CoV-2 antiviral, with an affinity strength equal to Chloroquine (HY-17589A) and Favipiravir (HY-14768).
    Antioxidant agent-9
  • HY-145277
    SARS-CoV-2-IN-11
    		Inhibitor
    SARS-CoV-2-IN-11 is a potent and nontoxic inhibitor of SARS-CoV-2 3CL protease (3CLpro) with an IC50 and EC50 of 0.17 and 1.45 nM, respectively. SARS-CoV-2 3C-like protease (3CLpro), an enzyme essential for viral replication, is an attractive target for intervention. SARS-CoV-2-IN-11 may lead to the emergence of effective SARS-CoV-2-specific antivirals.
    SARS-CoV-2-IN-11
  • HY-183266
    SR-A-174
    SR-A-174 is a SARS-CoV-2 MPro inhibitor with an IC50 of 0.060 μM. SR-A-174 has limited cell permeability and exhibits low activity in cells expressing MPro-eGFP, with a cellular IC50 > 10 μM. SR-A-174 can be used in COVID-19-related research.
    SR-A-174
  • HY-105086
    Pamaqueside
    		Inhibitor
    Pamaqueside (CP148623) is a cholesterol absorption inhibitor and a potent binder of the SARS-CoV-2 receptor-binding domain (RBD), which may inhibit viral cellular entry. Pamaqueside can be utilized in metabolic and antiviral research.
    Pamaqueside
  • HY-155416
    M56-S2 iodide
    		Inhibitor
    M56-S2 iodide is a SARS-CoV-2 Mpro inhibitor (IC50=4.0 μM). M56-S2 iodide showed good oral bioavailability and low toxicity in ADMET prediction. M56-S2 iodide has good drug potential and can be used in antiviral (such as SARS-CoV-2) research.
    M56-S2 iodide
  • HY-151267
    SARS-CoV-2-IN-25
    		Inhibitor
    SARS-CoV-2-IN-25 (Compound CP026) is a potent SARS-CoV-2 spike pseudoparticle transduction inhibitor with an IC50 of 1.6 μM. SARS-CoV-2-IN-25 inhibits enveloped viruses and liposomes.
    SARS-CoV-2-IN-25
  • HY-149319
    ZINC61142882
    		Inhibitor
    ZINC61142882 is an inhibitor of the SARS-CoV-2 Nsp14 N7-Methyltransferase (IC50: 6 μM).
    ZINC61142882
  • HY-169977
    CKP-25
    		Inhibitor
    CKP-25 is an inhibitor for the interaction between Spike RBD-ACE2, that prevents the virus from entering the host cell, thereby reducing the replication and virus infection. CKP-25 inhibits SARS-CoV-2 with IC50 of 3.5 μM in Vero E6 cell.
    CKP-25
  • HY-144799
    FWM-4
    		Inhibitor
    FWM-4 is a potent SARS-COV-2 NSP13 helicase enzyme inhibitor.
    FWM-4
  • HY-169256
    ZINC4497834
    		Inhibitor
    ZINC4497834 is an inhibitor of SARS-CoV-2 major protease Mpro. ZINC4497834 can be used in anti-COVID19 research.
    ZINC4497834
  • HY-151535
    SARS-CoV-2 3CLpro-IN-5
    		Inhibitor
    SARS-CoV-2 3CLpro-IN-5 is a covalent inhibitor of 3C-like protease (3CLpro). SARS-CoV-2 3CLpro-IN-5 has inhibitory activity for 3CLpro with an IC50 value of 3.8 nM. SARS-CoV-2 3CLpro-IN-5 has 9.0% oral bioavailability (BA). SARS-CoV-2 3CLpro-IN-5 can be used for the research of coronavirus disease 2019 (COVID-19).
    SARS-CoV-2 3CLpro-IN-5
Cat. No. Product Name / Synonyms Species Source